Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer’s therapy.
AI predicts liver cancer risk with “high accuracy”
A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
